Published in
American Society of Hematology, Blood, 4(132), p. 405-412
DOI: 10.1182/blood-2018-03-836528
Links
Tools
Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL
Journal article published in 2018 by
Anna Maria Testi 
,
Andrea Pession ,
Daniela Diverio ,
David Grimwade,
Brenda Gibson,
Amilcar Cardoso de Azevedo,
Lorena Moran,
Guy Leverger,
Sarah Elitzur,
Henrik Hasle,
Jutte van der Werff ten Bosch,
Owen Smith,
Marisa De Rosa,
Alfonso Piciocchi ,
Francesco Lo Coco
and other authors.
,
Andrea Pession ,
Daniela Diverio ,
David Grimwade,
Brenda Gibson,
Amilcar Cardoso de Azevedo,
Lorena Moran,
Guy Leverger,
Sarah Elitzur,
Henrik Hasle,
Jutte van der Werff ten Bosch,
Owen Smith,
Marisa De Rosa,
Alfonso Piciocchi ,
Francesco Lo Coco
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points Risk-adapted therapy allowed achieving remarkable cure rates in an international trial on childhood APL. Reduction of the anthracycline cumulative dose coupled with ATRA extended use does not compromise the outcome of children with APL.